title: The impact of recently published negative erythropoiesis-stimulating agent studies on the clinical management of cancer-related anemia at a single center.
abstract: OBJECTIVE
  Anemia in cancer patients is common, but often under-recognized and under-treated. Erythropoiesis stimulating agents (ESAs) are widely used to prevent and treat cancer and chemo- therapy-related anemia, but recent studies suggest a negative impact on disease progression and survival associated with their use. This retrospective study describes the prevalence of anemia in cancer patients and recent trends in its management given the negative studies.
  
  
  METHODS
  All consecutive adult cancer patients (n=959) admitted to regular medical units over one year were reviewed. Patients with a hemoglobin (Hb) value <12 g/dL on admission were considered anemic. Information on the primary tumor, main reasons for admission and treatment given were collected.
  
  
  RESULTS
  At the time of enrollment, anemia was detected in 755 (78.7%) patients. The mean Hb value for anemic patients was 9.5 g/dL. Prevalence and severity of anemia varied according to tumor type and reason for admission. The majority (68.6%) of the anemic patients were not offered treatment. The mean Hb value at which treatment was started was 8.0 g/dL. Anemia treatment was related to its severity; treatment rates were 94.4%, 32.9%, and 5.0% in patients with severe, moderate and mild anemia, respectively (P<.0001). Blood transfusion was used the most while ESAs were rarely used. Length of hospital stay was affected by the presence of anemia (7.2 days in anemic patients vs. 4.85 days in nonanemic patients) (P<.001).
  
  
  CONCLUSIONS
  Blood transfusion was used the most for cancer-related anemia, while ESAs were rarely used. The majority of patients with moderate anemia were not treated, including patients on active chemotherapy. Better guidelines addressing anemia management in this subgroup of patients are highly needed.
authors.affiliation: King Hussein Cancer Center, Amman, Jordan. habdelrazeq@khcc.jo
authors.forename: Hikmat
authors.initials: H
authors.lastname: Abdel-Razeq
authors.forename: Shadi
authors.initials: S
authors.lastname: Hijjawi
authors.forename: Hazem
authors.initials: H
authors.lastname: Abdulelah
authors.forename: Rula
authors.initials: R
authors.lastname: Amarin
authors.forename: Majid
authors.initials: M
authors.lastname: Asawaeer
authors.forename: Haitham
authors.initials: H
authors.lastname: Shaheen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D001803:Blood Transfusion; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D015995:Prevalence; D012189:Retrospective Studies
chemical_list: D006397:Hematinics; D006454:Hemoglobins